Cytotheryx Secures $60M Series A, Boosts Liver Cell Therapy Development
January 13, 2026, 9:34 am
Location: United States, Minnesota, Rochester
Employees: 10001+
Founded date: 1978
Total raised: $1.38B
Cytotheryx, a preclinical cell therapy firm, secured $60 million in Series A funding. Ouroboros Family Founders Fund I led the round. Significant debt financing from QRS Investments boosts facility and GMP manufacturing expansion. This Mayo Clinic spinout targets acute, chronic, and rare genetic liver diseases. The capital accelerates multiple programs toward clinical development. It builds critical infrastructure for scalable, therapeutic-grade liver cell production. Cytotheryx aims to revolutionize liver disease treatment, deploying functional primary human hepatocytes across diverse therapeutic approaches.
Cytotheryx makes big moves. The preclinical cell therapy company secured a lead term sheet for a $60 million Series A funding round. Ouroboros Family Founders Fund I, LP spearheaded this equity investment. This capital injection marks a significant milestone. It propels Cytotheryx’s mission to transform liver disease treatment.
Additional debt financing bolsters the company’s position. QRS Investments, LLC provided this separate debt facility. The combined funding package is strategic. It supports rapid expansion and program acceleration. Cytotheryx can now significantly scale its operations.
The company focuses on liver disease. This condition affects millions worldwide. Acute liver failure, chronic liver conditions, and rare genetic disorders present immense medical challenges. Current treatments often offer limited solutions. Many patients face dire prognoses. Liver transplantation remains a critical but scarce option. Cytotheryx offers a new paradigm.
Their core technology is revolutionary. Cytotheryx specializes in primary human hepatocytes. These cells are essential for liver function. Producing them at a clinical scale is notoriously difficult. Manufacturing consistency, supply, and functional quality are major hurdles for the broader field. Cytotheryx developed a differentiated platform. It enables scalable production of these crucial cells. This breakthrough addresses a critical bottleneck in cell therapy development.
The proprietary "bio-incubator" platform is central to their strategy. This system allows for large-scale liver cell production. It ensures consistency and high functional quality. This robust manufacturing capability distinguishes Cytotheryx. It positions them as a leader in liver-directed cell therapies.
Cytotheryx’s technology portfolio extends further. It includes a bioartificial liver support system. This system targets acute liver failure. Acute liver failure demands immediate, effective intervention. This system could provide vital time for patients. It offers a bridge to recovery or transplantation.
Another key component is a universal liver cell therapy concept. This therapy aims for transplantation. It targets patients with rare genetic and chronic liver diseases. Such conditions often lack effective long-term treatments. A universal cell therapy could significantly expand treatment access. It offers hope for patients awaiting liver transplants.
The $60 million Series A funding fuels ambitious plans. It accelerates multiple programs. These programs will move toward clinical development. Robust clinical trials are the next step. They will test the safety and efficacy of Cytotheryx’s therapies. This funding brings life-changing treatments closer to patients.
The debt financing serves a crucial purpose. It expands the company’s manufacturing and operational footprint. This includes acquiring additional real estate. It will also increase GMP manufacturing capacity. GMP, or Good Manufacturing Practice, is vital for pharmaceutical production. It ensures product quality, safety, and purity. Building out GMP capacity is a significant investment. It signifies Cytotheryx’s commitment to clinical-grade production.
Operational scale-up is another priority. This means enhancing infrastructure across the board. Research and development will benefit. So will administrative and support functions. A larger, more efficient operation supports accelerated growth. It prepares the company for future demands.
Cytotheryx originated as a Mayo Clinic spinout. This affiliation underscores its scientific foundation. Mayo Clinic is a globally recognized medical institution. Its spinouts often leverage cutting-edge research. They translate scientific discoveries into clinical applications. This pedigree lends credibility to Cytotheryx’s innovative approach.
The investment reflects strong confidence. Investors see immense potential. They recognize Cytotheryx's platform. They believe in its ability to meaningfully advance liver disease treatment. The strategic combination of equity and debt financing supports both program advancement and infrastructure buildout. This dual approach maximizes growth potential. It ensures long-term sustainability.
The cell therapy market is dynamic. It is experiencing rapid growth. Billions of dollars flow into biotechnology. Investors seek innovative solutions for unmet medical needs. Liver disease represents a significant, underserved market. Cytotheryx is well-positioned within this landscape. Its focus on scalable, functional hepatocytes addresses a core challenge in the field.
Liver diseases pose a severe global health burden. Conditions like cirrhosis, hepatitis, and fatty liver disease affect millions. They lead to significant morbidity and mortality. New therapeutic strategies are urgently needed. Cytotheryx aims to provide these solutions. Its approach could reduce the need for organ transplants. It could improve quality of life for countless patients.
Dr. John Swart leads Cytotheryx as CEO. His leadership guides the company. He steers its preclinical development efforts. The team focuses on scientific rigor and clinical translation. This leadership is critical for navigating complex development pathways.
The financing package is a pivotal milestone. It empowers Cytotheryx. It enables the company to move rapidly. It builds necessary capabilities. It secures resources for future clinical and manufacturing demands. This is not just a funding round. It is an investment in the future of liver disease treatment.
Cytotheryx envisions a future. Patients with severe liver conditions will have new options. Their therapies will be accessible and effective. The company’s innovative platforms promise to deliver on this vision. The path to the clinic is now clearer. The impact on patients could be profound. This funding marks the beginning of a new chapter for liver disease therapy.
Cytotheryx makes big moves. The preclinical cell therapy company secured a lead term sheet for a $60 million Series A funding round. Ouroboros Family Founders Fund I, LP spearheaded this equity investment. This capital injection marks a significant milestone. It propels Cytotheryx’s mission to transform liver disease treatment.
Additional debt financing bolsters the company’s position. QRS Investments, LLC provided this separate debt facility. The combined funding package is strategic. It supports rapid expansion and program acceleration. Cytotheryx can now significantly scale its operations.
The company focuses on liver disease. This condition affects millions worldwide. Acute liver failure, chronic liver conditions, and rare genetic disorders present immense medical challenges. Current treatments often offer limited solutions. Many patients face dire prognoses. Liver transplantation remains a critical but scarce option. Cytotheryx offers a new paradigm.
Their core technology is revolutionary. Cytotheryx specializes in primary human hepatocytes. These cells are essential for liver function. Producing them at a clinical scale is notoriously difficult. Manufacturing consistency, supply, and functional quality are major hurdles for the broader field. Cytotheryx developed a differentiated platform. It enables scalable production of these crucial cells. This breakthrough addresses a critical bottleneck in cell therapy development.
The proprietary "bio-incubator" platform is central to their strategy. This system allows for large-scale liver cell production. It ensures consistency and high functional quality. This robust manufacturing capability distinguishes Cytotheryx. It positions them as a leader in liver-directed cell therapies.
Cytotheryx’s technology portfolio extends further. It includes a bioartificial liver support system. This system targets acute liver failure. Acute liver failure demands immediate, effective intervention. This system could provide vital time for patients. It offers a bridge to recovery or transplantation.
Another key component is a universal liver cell therapy concept. This therapy aims for transplantation. It targets patients with rare genetic and chronic liver diseases. Such conditions often lack effective long-term treatments. A universal cell therapy could significantly expand treatment access. It offers hope for patients awaiting liver transplants.
The $60 million Series A funding fuels ambitious plans. It accelerates multiple programs. These programs will move toward clinical development. Robust clinical trials are the next step. They will test the safety and efficacy of Cytotheryx’s therapies. This funding brings life-changing treatments closer to patients.
The debt financing serves a crucial purpose. It expands the company’s manufacturing and operational footprint. This includes acquiring additional real estate. It will also increase GMP manufacturing capacity. GMP, or Good Manufacturing Practice, is vital for pharmaceutical production. It ensures product quality, safety, and purity. Building out GMP capacity is a significant investment. It signifies Cytotheryx’s commitment to clinical-grade production.
Operational scale-up is another priority. This means enhancing infrastructure across the board. Research and development will benefit. So will administrative and support functions. A larger, more efficient operation supports accelerated growth. It prepares the company for future demands.
Cytotheryx originated as a Mayo Clinic spinout. This affiliation underscores its scientific foundation. Mayo Clinic is a globally recognized medical institution. Its spinouts often leverage cutting-edge research. They translate scientific discoveries into clinical applications. This pedigree lends credibility to Cytotheryx’s innovative approach.
The investment reflects strong confidence. Investors see immense potential. They recognize Cytotheryx's platform. They believe in its ability to meaningfully advance liver disease treatment. The strategic combination of equity and debt financing supports both program advancement and infrastructure buildout. This dual approach maximizes growth potential. It ensures long-term sustainability.
The cell therapy market is dynamic. It is experiencing rapid growth. Billions of dollars flow into biotechnology. Investors seek innovative solutions for unmet medical needs. Liver disease represents a significant, underserved market. Cytotheryx is well-positioned within this landscape. Its focus on scalable, functional hepatocytes addresses a core challenge in the field.
Liver diseases pose a severe global health burden. Conditions like cirrhosis, hepatitis, and fatty liver disease affect millions. They lead to significant morbidity and mortality. New therapeutic strategies are urgently needed. Cytotheryx aims to provide these solutions. Its approach could reduce the need for organ transplants. It could improve quality of life for countless patients.
Dr. John Swart leads Cytotheryx as CEO. His leadership guides the company. He steers its preclinical development efforts. The team focuses on scientific rigor and clinical translation. This leadership is critical for navigating complex development pathways.
The financing package is a pivotal milestone. It empowers Cytotheryx. It enables the company to move rapidly. It builds necessary capabilities. It secures resources for future clinical and manufacturing demands. This is not just a funding round. It is an investment in the future of liver disease treatment.
Cytotheryx envisions a future. Patients with severe liver conditions will have new options. Their therapies will be accessible and effective. The company’s innovative platforms promise to deliver on this vision. The path to the clinic is now clearer. The impact on patients could be profound. This funding marks the beginning of a new chapter for liver disease therapy.